慢性痛风患者血清尿酸——它会成为风湿科首个被验证的可溶性生物标志物吗？
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?
机构信息
Department of Medicine, University of Otago, Christchurch, New Zealand.
出版信息
J Rheumatol. 2011 Jul;38(7):1462-6. doi: 10.3899/jrheum.110273.
OBJECTIVE
To summarize evidence for and endorsement of serum urate (SU) as having fulfilled the OMERACT filter as a soluble biomarker in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10).
METHODS
Data were presented to support the use of SU as a soluble biomarker in chronic gout and specifically the ability to utilize it to predict future patient-reported outcomes.
RESULTS
SU was accepted as having fulfilled the OMERACT filter by 78% of voters. However, consensus was not obtained regarding its use as a soluble biomarker in chronic gout. Although the majority of the criteria for a soluble biomarker were fulfilled, the key criterion of association of the biomarker with outcomes was not agreed upon. It was agreed that the appropriate choice of endpoint must be linked to its clinical importance to the individual with the disorder and its temporal relationship to the intervention. Appropriate outcomes in chronic gout may therefore include gout flares, reduction in tophi, and patient-reported outcomes.
CONCLUSION
SU is a critical outcome measure. It has the potential to fulfil criteria for a soluble biomarker. Further analyses of existing data from randomized controlled trials will be required to determine whether SU can predict future important outcomes, in particular disability.
目的
总结证据并支持尿酸（SU）作为可溶性生物标志物在 2010 年风湿病疗效评价标准（OMERACT10）会议上满足慢性痛风的 OMERACT 过滤器标准。
方法
提出 SU 作为慢性痛风可溶性生物标志物的数据，特别是利用其预测未来患者报告结局的能力。
结果
78%的投票者认为 SU 满足 OMERACT 过滤器标准。然而，对于 SU 在慢性痛风中的可溶性生物标志物的使用并未达成共识。尽管满足了可溶性生物标志物的大多数标准，但生物标志物与结局相关的关键标准并未得到一致认可。人们一致认为，终点的适当选择必须与其对个体患者的临床重要性及其与干预的时间关系相关。因此，慢性痛风的适当结局可能包括痛风发作、痛风石减少和患者报告结局。
结论
SU 是一个重要的结局衡量指标。它有潜力满足可溶性生物标志物的标准。需要进一步分析随机对照试验的现有数据，以确定 SU 是否可以预测未来的重要结局，特别是残疾。
Zotero 插件